- Home
- ACRE vs AMRN Comparison
ACRE vs AMRN Comparison
Compare ACRE & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | AMRN |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 304.6M |
| IPO Year | 2011 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ACRE | AMRN |
|---|---|---|
| Price | $5.35 | $14.79 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 5 | 1 |
| Target Price | $5.38 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 395.8K | 41.6K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 11.15% | N/A |
| EPS Growth | 26.17 | ★ 55.00 |
| EPS | ★ 1.35 | N/A |
| Revenue | $54,833,000.00 | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | $1.26 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.71 | $9.44 |
| 52 Week High | $5.89 | $20.90 |
Technical Indicators
Market Signals| Indicator | ACRE | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 66.33 | 46.44 |
| Support Level | $4.66 | $13.65 |
| Resistance Level | $5.55 | $14.49 |
| Average True Range (ATR) | 0.12 | 0.56 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 98.64 | 40.91 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.